Article Text

Download PDFPDF

Gastric microbiota in the functional dyspepsia patients treated with probiotic yogurt
  1. Hirohiko Nakae1,
  2. Ayumi Tsuda2,
  3. Takashi Matsuoka3,4,
  4. Tetsuya Mine1,
  5. Yasuhiro Koga4
  1. 1Department of Gastrointestinal Medicine, Tokai University School of Medicine, Isehara, Japan
  2. 2Department of General Medicine, Tokai University School of Medicine, Isehara, Japan
  3. 3Koikeya Co., Ltd, Itabashi-Ku, Tokyo, Japan
  4. 4Laboratory for Infectious Diseases, Tokai University School of Medicine, Isehara, Japan
  1. Correspondence to Dr Yasuhiro Koga; yasuhiro{at}is.icc.u-tokai.ac.jp

Abstract

Objective To investigate the structure of the gastric microbiota in functional dyspepsia (FD) and its role in the pathophysiology.

Design We compared the basic physiological properties of the gastric fluid (GF) and the structure of the microbiota in the GF of 44 healthy control (HC) participants and 44 patients with FD. We then treated the patients with FD with a yogurt containing a probiotic strain of Lactobacillus gasseri OLL2716 (LG21 yogurt) and investigated the effects on the bacteriological parameters and symptoms to examine the relationship between them.

Results The volume of GF recovered from the stomach after overnight fasting was greater in the patients with FD than in the HCs, and decreased in the patients with FD whose symptoms were improved by the LG21 yogurt treatment. An analysis using a terminal restriction fragment polymorphism method demonstrated that the overall structure of the bacterial community and the abundance of genus Prevotella in the GF of the patients in the FD group were significantly different from those in the HC group. In the patients with FD, this bacteriological change was restored by treatment with LG21 yogurt. A significant inverse correlation was found between the abundance of Prevotella and the severity of postprandial distress-like symptoms in patients with FD who received LG21 yogurt.

Conclusions Significant dysbiosis was found in the GF microbiota of patients with FD and considered to be involved in the pathogenesis. The abundance of genus Prevotella in the GF may be used as a biomarker of the efficacy of the treatment of FD.

Trial registration number UMINCTR000022026.

  • FUNCTIONAL DYSPEPSIA
  • PROBIOTICS
  • BACTERIAL PATHOGENESIS

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.